<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492373</url>
  </required_header>
  <id_info>
    <org_study_id>Si 033/2015</org_study_id>
    <nct_id>NCT02492373</nct_id>
  </id_info>
  <brief_title>Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser</brief_title>
  <official_title>Effect of Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation Following Q-switched Nd:YAG 532 nm Laser for Treatment of Facial Lentigines - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the benefit of the application of topical high potency steroid on the
      incidence of post inflammatory hyperpigmentation after laser treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The incidence of post inflammatory hyperpigmentation (PIH) after treating lentigines
           with Q-switched Nd:YAG laser was 78.3%.

        -  It has been found that the incidence of PIH decreased to 40% after applied topical high
           potency steroid 2 days after the laser treatment.

        -  By these anti-inflammatory and anti-PIH effects of the high potency steroid, the
           investigators aimed that the application of steroid 2 days before and 2 days after the
           laser treatment would be better reduction in the incidence of PIH after Q-switched
           Nd:YAG laser.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of post inflammatory hyperpigmentation</measure>
    <time_frame>2 weeks</time_frame>
    <description>By investigator's observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects of topical steroid</measure>
    <time_frame>Follow-up 2, 3, 4, 8, 12 and 24 weeks after the last treatment</time_frame>
    <description>By investigators' observation of telangiectasia, erythema or atrophy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patients satisfaction</measure>
    <time_frame>Follow-up 4, 8, 12 and 24 weeks after the last treatment</time_frame>
    <description>By using Quartile grading scale of improvement; 0 = not improve, 1= 1-25% improvement, 2 = 26-50% improvement, 3 = 51-75% improvement and 4 = 76-100% improvement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Lentigines</condition>
  <condition>Post Inflammatory Hyperpigmentation</condition>
  <arm_group>
    <arm_group_label>laser+steroid 2 days before and after laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Before lentigines' treatment with Qs Nd:YAG 532 nm laser, topical 0.05% Clobetasol propionate ointment was applied 2 days on the lesion. Then applied 2 days after the treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laser+steroid 2 days after laser</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Controlled side. Applied topical 0.05% Clobetasol propionate ointment only 2 days after the laser treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical 0.05% Clobetasol propionate ointment</intervention_name>
    <description>Apply only on the treated area twice a day as mentions</description>
    <arm_group_label>laser+steroid 2 days before and after laser</arm_group_label>
    <arm_group_label>laser+steroid 2 days after laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Q switched Nd:YAG laser 532 nm</intervention_name>
    <description>Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.</description>
    <arm_group_label>laser+steroid 2 days before and after laser</arm_group_label>
    <arm_group_label>laser+steroid 2 days after laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having multiple lentigines on both sides of the face

          -  Fitzpatrick skin phototype 3-5

        Exclusion Criteria:

          -  Patients with lesions with any clinical suspicion of being pre-cancerous or skin
             malignancies of any kind

          -  Patients who have photosensitive dermatoses

          -  Pregnancy and lactation woman

          -  Patients with wound infections (herpes, other) on the day of treatment

          -  Patients with moderate and severe inflammatory acne, Immunosuppressed patients,
             history of vitiligo

          -  Patients with unrealistic concerns/expectations and inability to do the appropriate
             post-operative care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woraphong Manuskiatti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Siriraj Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Jun HJ, Cho SH, Lee JD, Kim HS. A split-face, evaluator-blind randomized study on the early effects of Q-switched Nd:YAG laser plus Er:YAG micropeel (combined therapy) versus Q-switched Nd:YAG alone in light solar lentigines in Asians. Lasers Med Sci. 2014 May;29(3):1153-8. doi: 10.1007/s10103-013-1489-9. Epub 2013 Nov 29.</citation>
    <PMID>24292155</PMID>
  </results_reference>
  <results_reference>
    <citation>Ho SG, Yeung CK, Chan NP, Shek SY, Chan HH. A comparison of Q-switched and long-pulsed alexandrite laser for the treatment of freckles and lentigines in oriental patients. Lasers Surg Med. 2011 Feb;43(2):108-13. doi: 10.1002/lsm.21045.</citation>
    <PMID>21384391</PMID>
  </results_reference>
  <results_reference>
    <citation>Takiwaki H, Shirai S, Kohno H, Soh H, Arase S. The degrees of UVB-induced erythema and pigmentation correlate linearly and are reduced in a parallel manner by topical anti-inflammatory agents. J Invest Dermatol. 1994 Nov;103(5):642-6.</citation>
    <PMID>7963648</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheyasak N, Manuskiatti W, Maneeprasopchoke P, Wanitphakdeedecha R. Topical corticosteroids minimise the risk of postinflammatory hyper-pigmentation after ablative fractional CO2 laser resurfacing in Asians. Acta Derm Venereol. 2015 Feb;95(2):201-5. doi: 10.2340/00015555-1899.</citation>
    <PMID>24854088</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>May 31, 2016</last_update_submitted>
  <last_update_submitted_qc>May 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Woraphong Manuskiatti, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Post inflammatory hyperpigmentation</keyword>
  <keyword>topical high potency steroid</keyword>
  <keyword>Qs NdYAG laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lentigo</mesh_term>
    <mesh_term>Hyperpigmentation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

